|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT[[Foscarnet sodium]] |
| {{Foscarnet}}
| |
| {{CMG}}
| |
| | |
| ==Overview==
| |
| '''Foscarnet''' is the [[conjugate base]] of the [[chemical compound]] with the [[chemical formula|formula]] HO<sub>2</sub>CPO<sub>3</sub>H<sub>2</sub>. This [[phosphonic acid]] derivative is (marketed by [[AstraZeneca]] as foscarnet [[sodium]] under the trade name Foscavir®) is an [[antiviral]][[medication]] used to treat [[herpes viruses]], including [[cytomegalovirus]] (CMV) and [[herpes simplex]] viruses types 1 and 2 (HSV-1 and HSV-2). It is particularly used to treat [[CMV retinitis]].
| |
| ==Category==
| |
| Antiviral
| |
| | |
| ==US Brand Names==
| |
| FOSCAVIR<sup>®</sup>
| |
| | |
| ==FDA Package Insert==
| |
| | |
| ''' [[Foscarnet description|Description]]'''
| |
| '''| [[Foscarnet clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Foscarnet microbiology|Microbiology]]'''
| |
| '''| [[Foscarnet indications and usage|Indications and Usage]]'''
| |
| '''| [[Foscarnet contraindications|Contraindications]]'''
| |
| '''| [[Foscarnet warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Foscarnet adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Foscarnet drug interactions|Drug Interactions]]'''
| |
| '''| [[Foscarnet overdosage|Overdosage]]'''
| |
| '''| [[Foscarnet clinical studies|Clinical Studies]]'''
| |
| '''| [[Foscarnet dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Foscarnet how supplied|How Supplied]]'''
| |
| '''| [[Foscarnet labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| FOSCAVIR is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2).
| |
| | |
| FOSCAVIR exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. FOSCAVIR does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to FOSCAVIR. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to FOSCAVIR and may not respond to therapy with FOSCAVIR. The combination of FOSCAVIR and ganciclovir has been shown to have enhanced activity in vitro.
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antibiotics]]
| |
| [[Category:Wikinfect]]
| |